Lucius Sparsentan™ | Instruction Manual v.1.0

Designation: Dual Endothelin-Angiotensin Receptor Antagonist (DEARA)
Model: Lucius Sparsentan
Strength: 200mg / 400mg
Indication: IgA Nephropathy (Primary Proteinuria Reduction System)

1. SYSTEM OVERVIEW

The Lucius Sparsentan unit is a first-in-class, orally bioavailable dual endothelin angiotensin receptor antagonist engineered for targeted proteinuria reduction in IgA nephropathy. It is indicated for:

• Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression

Mechanism of Action:
Dual blockade of:

• Endothelin Type A (ETₐ) receptors → inhibits ET-1 mediated profibrotic/inflammatory pathways

• Angiotensin II Type 1 (AT₁) receptors → inhibits RAAS-mediated glomerular hypertension/hypertrophy

2. INITIALIZATION & DOSING

Recommended Loading Sequence:

• Weeks 1-3: 200mg once daily

• Week 4 onward: 400mg once daily (if tolerated)

Administration Protocol:

• Administer whole with water. Do not crush or split.

• Take consistently with or without food.

• Avoid evening dosing to minimize orthostatic hypotension risk.

Dose Modification Modules:

• Hepatic impairment: Avoid use in severe impairment (Child-Pugh C)

• Not recommended with strong CYP3A4 inducers

3. MONITORING & FEEDBACK LOOPS

Baseline & Routine Surveillance Required:

• Hepatic: LFTs at baseline, monthly × 6mo, then quarterly

• Renal: UPCR, eGFR, serum creatinine

• Cardiovascular: BP monitoring (especially orthostatic), fluid status

• Pregnancy tests: Monthly in females of reproductive potential

Performance Metrics:

• ≥30% reduction in UPCR expected within 3-6 months

• Slowed eGFR decline trajectory

4. ADVERSE EVENT PROTOCOLS

5. DRUG INTERACTION ALGORITHMS

Contraindicated Combinations:

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)

• Other ERA/RAAS agents (e.g., ACEi, ARB, aliskiren)

Use With Caution:

• Moderate CYP3A4 inhibitors (e.g., fluconazole)

• NSAIDs, potassium-sparing diuretics

• Antihypertensives (additive BP effects)

6. SAFETY PROTOCOLS

• Pregnancy: Contraindicated (Boxed Warning - Embryofetal Toxicity)

• Hepatic: Contraindicated in liver disease

• Missed Dose: Skip if >12h late; do not double dose

• Discontinuation: Taper over 2-4 weeks to avoid rebound hypertension

7. STORAGE & HANDLING

• Store at 20°–25°C (68°–77°F)

• Keep in original container with desiccant

• Protect from moisture and light

8. DISCONTINUATION CRITERIA

• Confirmed pregnancy

• Persistent ALT/AST >3x ULN

• Unmanageable hyperkalemia/hypotension

• Disease progression requiring alternative therapy

  
  whatsapp:+852 61905607
  wechat:yindu7689